Kadimastem and Merck Serono Enter Neurodegenerative Disease Partnership

Kadimastem, an Israeli biotechnology company focused on stem-cell therapies for diabetes and neurodegenerative diseases, has entered into a drug screening collaboration agreement with Merck Serono. The initial therapeutic focus is on multiple sclerosis (MS), leveraging Kadimastem’s drug screening platform of stem cell-derived oligendendrocytes and Merck’s compound libraries. The collaboration builds on a prior collaboration between the two companies from 2012 in the area of drug screening for MS. With Kadimastem’s interest in other diseases, such as ALS, the collaboration may expand into drug screening for other neurodegenerative diseases using Kadimastem’s platform for stem cell-derived astrocytes. Merck will pay Kadimastem an up-front fee as well as undisclosed milestone payments.

Kadimastem, an Israeli biotechnology company focused on stem-cell therapies for diabetes and neurodegenerative diseases, has entered into a drug screening collaboration agreement with Merck Serono. The initial therapeutic focus is on multiple sclerosis (MS), leveraging Kadimastem’s drug screening platform of stem cell-derived oligendendrocytes and Merck’s compound libraries. The collaboration builds on a prior collaboration between the two companies from 2012 in the area of drug screening for MS. With Kadimastem’s interest in other diseases, such as ALS, the collaboration may expand into drug screening for other neurodegenerative diseases using Kadimastem’s platform for stem cell-derived astrocytes. Merck will pay Kadimastem an up-front fee as well as undisclosed milestone payments.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail